annb0t
Top 20
Revenue: Increased by 56% compared to the prior year. Adjusted EBITDA: Improved by 70% to $99 million. Operating Cash Inflow: Improved by 80%. Profit After Tax: Increased by 860%. End of Year Cash Position: $710 million, bolstered by a convertible bond placement. R&D Investment: $195 million, focusing on regulatory filings and inventory scale-up. Gross Margin: Improved by 3% to 65%. Precision Medicine Revenue Growth: 55% increase in sales of Aleix. Therapeutic Pipeline Investment: Increased by 7...
>>> Read more: Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...
>>> Read more: Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...
